Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG

Melanoma Stage III Clinical Trial

— MelanooMSOT  

Official title:

Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MultiSpectral Optoacoustic Tomography (MSOT) and IndoCyanine Green (ICG)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05467137
• Other study ID #: 202100685
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: September 2022
• Est. completion date: March 2023

Study information

• Verified date: July 2022
• Source: University Medical Center Groningen
• Contact: Jutten
• Phone: 0031 50 361 6161
• Email: e.jutten[@]umcg.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study the investigators try to identify the sentinel lymph node in patients with stage Ib-III melanoma in a non-invasive manner without the use of a radioactive tracer by using the new MSOT technology.

Description:

Over the past few decades, melanoma has been one of the fastest-growing cancers and the incidence rate of melanoma is still increasing. Standard treatment for melanoma is wide (re)excision. Sentinel lymph node (SLN) biopsy (SLNB) is recommended for patients with melanoma of AJCC stage pT1b or higher according to Dutch guidelines. SLNB provides essential staging information that impacts on the clinical management of patients with melanoma, and the presence of SLN metastasis indicates a significantly worse prognosis. However, the overall complication rate of SLNB is high.

Currently, lymphoscintigraphy using 99mTc-nanocolloid Technetium-99m-nanocolloïd (Tc99m) is the gold standard to identify the sentinel lymph node. However, there are various disadvantages of using 99mTc-nanocolloidTc99m: the involvement of radioisotopes represents a radioactive burden for patients and caregivers, the lymphoscintigraphic imaging has poor spatial resolution, and the involvement of radioisotopes is expensive and creates logistic challenges. Therefore, in this study the goal is to identify the sentinel lymph node in a non-invasive manner without the use of a radioactive tracer. The investigators try to reach this goal by using the fluorophore dye IndoCyanine Green (ICG) and multispectral optoacoustic imaging (MSOT).

MSOT is a new, but increasingly used, imaging modality that has emerged the field of optical imaging. MSOT is based on a highly powerful pulsed laser in different wavelengths. Photo absorbing molecules absorb laser light in a specific wavelength, undergo thermal expansion and create soundwaves which can be detected by special transducers. The MSOT combines conventional ultrasonography with optoacoustic imaging which gives both anatomical and biological information and is currently available in the University Medical Centre Groningen (UMCG).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: March 2023
• Est. primary completion date: November 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with grade Ib- III melanoma scheduled for SLNB and/or surgical excision.

• Patients must be > 18 years old and be able to give informed consent.

• Skintype I-IV following Fitzpatrick skin classification (MSOT less reliable in skin types >IV)

Exclusion Criteria:

• Apparent hyperthyroidism or autonomous thyroid adenoma of the thyroid gland

• Prior surgery or radiotherapy on involved lymph nodes / area

• Major surgery within 28 days before tracer administration

• Pregnant or nursing women, fertile women will need a negative pregnancy test prior to inclusion

• History of iodine allergy or anaphylactic reactions to insect bites

• Hypersensitivity to ICG or poorly tolerated ICG in the past

• Unexplained allergic reaction in the past

• Skin type >IV following Fitzpatrick skin classification (MSOT less reliable)

Related Conditions & MeSH terms

• Melanoma
• Melanoma Stage III
• Melanoma, Stage I
• Melanoma, Stage II

Intervention

Device:
• MSOT
MSOT imaging (after ICG injection)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center Groningen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concordance rate of SLNs identified by MSOT imaging and ICG versus the standard of care with 99mTc-nanocolloid Tc99m and lymphoscintigraphic imaging		Through study completion (an average of 1 year)
Secondary	Patient characteristics	Age, sex, BMI, history and morbidity, localization and extent of primary tumor, baseline blood count/liver and kidney function	Through study completion (an average of 1 year)